ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Syndax Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROE of 0.83%
- The company has been able to generate a Return on Equity (avg) of 0.83% signifying low profitability per unit of shareholders funds
2
With a growth in Net Sales of 794.9%, the company declared Very Positive results in Sep 25
- The company has declared positive results in Jan 70 after 11 consecutive negative quarters
- CASH AND EQV(HY) Highest at USD 891.21 MM
- INVENTORY TURNOVER RATIO(HY) Highest at 0.41 times
- DEBTORS TURNOVER RATIO(HY) Highest at 4.67 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 92.82%, its profits have fallen by -26.9%
4
Rising Promoter Confidence
- Promoters have increased their stake in the company by 1.77% over the previous quarter and currently hold 6.84% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
5
Market Beating Performance
- The stock has generated a return of 92.82% in the last 1 year, much higher than market (S&P 500) returns of 20.78%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Syndax Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Syndax Pharmaceuticals, Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Syndax Pharmaceuticals, Inc.
95.05%
0.33
68.74%
S&P 500
20.78%
1.08
19.33%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
136.12%
EBIT Growth (5y)
-221.63%
EBIT to Interest (avg)
-75.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.78
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.83%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.52
EV to EBIT
-3.63
EV to EBITDA
-3.63
EV to Capital Employed
26.52
EV to Sales
15.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-730.36%
ROE (Latest)
-212.79%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
CASH AND EQV(HY)
Highest at USD 891.21 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 0.41 times
DEBTORS TURNOVER RATIO(HY)
Highest at 4.67 times
NET SALES(Q)
Highest at USD 45.87 MM
OPERATING PROFIT(Q)
Highest at USD -57.42 MM
OPERATING PROFIT MARGIN(Q)
Highest at -125.18 %
PRE-TAX PROFIT(Q)
Highest at USD -60.72 MM
NET PROFIT(Q)
Highest at USD -60.72 MM
EPS(Q)
Highest at USD -0.7
-13What is not working for the Company
INTEREST(HY)
At USD 16.14 MM has Grown at 23,636.76%
OPERATING CASH FLOW(Y)
Lowest at USD -310.89 MM
ROCE(HY)
Lowest at -129.32%
Here's what is working for Syndax Pharmaceuticals, Inc.
Net Sales
At USD 45.87 MM has Grown at 266.97%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Net Sales
Highest at USD 45.87 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -57.42 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -125.18 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -60.72 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -60.72 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.7
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 891.21 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 0.41 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 4.67 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Syndax Pharmaceuticals, Inc.
Interest
At USD 16.14 MM has Grown at 23,636.76%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -310.89 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
